SUPRAX (cefixime)
SUPRAX is indicated for the treatment of Urinary Tract Infection; Otitis Media; Pharyngitis; Tonsillitis; Chronic Bronchitis; Gonorrhea.
How SUPRAX Works
Cefixime is a semisynthetic, third-generation cephalosporin that exerts bactericidal activity by inhibiting bacterial cell wall synthesis. It binds to specific penicillin-binding proteins
Development Insights
Details
- Status
- Discontinued
- First Approved
- 1989-04-28
- Patent Cliff
- 2028
- Routes
- ORAL
- Dosage Forms
- TABLET, CAPSULE, FOR SUSPENSION, TABLET, CHEWABLE
SUPRAX Approval History
What SUPRAX Treats
6 indicationsSUPRAX is approved for 6 conditions since its original approval in 1989. These indications span multiple therapeutic areas including oncology, immunology, and more.
- Urinary Tract Infection
- Otitis Media
- Pharyngitis
- Tonsillitis
- Chronic Bronchitis
- Gonorrhea
SUPRAX Competitive Set
ProThree rings of competition based on shared molecular targets and treated indications.
Indication competitors
Same indication, different mechanism — what else might this patient receive?
Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.
Drugs Similar to SUPRAX
3 of 20FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.
Clinical Trial Registry
9 trials| Trial | Sponsor ID | Phase | Status | Title |
|---|---|---|---|---|
| NCT05294588 | 21-0498 DMID 21-0018, U01AI162457-01 | Ph 2 | completed | Efficacy of Immunization With 4C-MenB in Preventing Experimental Urethral Infection With Neisseria Gonorrhoeae |
| NCT04349826 ACT-South Asia | 25NP | Ph 4 | completed | The Azithromycin and Cefixime Treatment of Typhoid in South Asia Trial (ACT-South Asia Trial) |
| NCT06090565 | 9937 | Ph 4 | completed | Cefixime Plus Doxycycline Compared to Ceftriaxone Plus Azithromycin for Treatment of Gonorrhoea |
| NCT03840811 results posted | 09-0106 | Ph 1 | completed | Experimental Human Infection With Neisseria Gonorrhoeae |
| NCT00786669 VITAC | VITAC | Ph 1 | completed | A Pilot Study of the Addition of Bevacizumab to VOIT Regimen for Relapsed/Refractory Pediatric Solid Tumors |
| NCT01595529 results posted | 09-0103 | Ph 2 | completed | The SCOUT Study: "Short Course Therapy for Urinary Tract Infections in Children" |
| NCT01949363 | 12-0025 HHSN272201500007I | Ph 1 | completed | The Pharmacokinetics of Extended Duration High-dose Cefixime for the Decreased Susceptibility of Neisseria Gonorrhoeae: A Phase I Pilot Study |
| NCT02708992 | 15-0031 HHSN272201500006I | Ph 1 | completed | Cefixime / Azithromycin pK Study |
| NCT01072136 results posted | 07-0082 | Ph 3 | terminated | Empiric Therapy of Mucopurulent Cervicitis (MPC) |
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
SUPRAX FDA Label Details
Indications & Usage
FDA Label (PDF)SUPRAX is indicated for the treatment of Urinary Tract Infection; Otitis Media; Pharyngitis; Tonsillitis; Chronic Bronchitis; Gonorrhea.
SUPRAX Patents & Exclusivity
Patents (1 active)
Pro Intelligence Preview
Deep insights for SUPRAX
Revenue Insights
- • Quarterly revenue tracking
- • Historical trend analysis
Patent Timeline
- • Cliff: 2028
- • 1 active patents
Trial Analysis
- • 9 total trials
- • Stage: Declining
Competitive Landscape
- • 20 similar drugs
- • Same target/indication analysis
Full approval history • All patents • Revenue trends • Competitor analysis
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.
How We Calculate These Metrics
Trial Activity Stage
Measures the current development activity pattern based on trial phases, status, and trends. Important: This measures R&D activity, not commercial lifecycle.
Trial statuses: "Active" means recruiting or ongoing. "Completed" means reached planned endpoint. "Terminated" means stopped early—often due to safety, efficacy, or business reasons.
- Growth: High proportion of early-phase trials (Phase 1/2), active development
- Expansion: Significant Phase 3 activity, approaching or pursuing approvals
- Mature: Substantial Phase 4 post-marketing studies
- Stable: Mixed phase distribution, steady development
- Declining: Low active trial ratio, reduced R&D investment